Alembic Pharma Q4 FY25: Sales up 17%, PAT falls 12%

Stock slips as latest session shows weakness

Alembic Pharma Ltd was trading at ₹791.3 in the latest session, down ₹13.04 from the previous close. The stock moved in a narrow band during the day, with an intraday low of ₹790 and a high of ₹802.25. Over the last one year, the stock delivered a return of -10.37%, based on the data provided. The one-month return was -0.5%, suggesting limited near-term momentum. The 52-week range stood wide, with a low of ₹725.2 and a high of ₹1,107.9. The counter was also flagged as a small-cap stock in the pharmaceuticals segment in the provided data. This price action set the backdrop for investors tracking recent earnings and margin movements.

Key price levels and the technical snapshot

The technical summary in the data listed a pivot level of 795.52. With the stock trading close to ₹791.3, the day’s price remained slightly below that pivot. The intraday range between ₹790 and ₹802.25 indicated that the market was still searching for direction. The 52-week high of ₹1,107.9 places the current price substantially below its peak, while the 52-week low of ₹725.2 remains a key downside reference. Separate snippets in the source also mention other price points such as ₹961 and ₹924 at different times, indicating the dataset contains multiple snapshots. Because these values are timestamped differently, they should not be treated as a single continuous series. What remains consistent is that the stock has seen meaningful swings within its yearly band. For traders, the proximity to the pivot and the day’s low can matter, but the dataset does not provide volume or broader index context.

Q4 FY25: Revenue grew, profit declined

For Q4 FY25, the company’s revenue from operations rose 17% year-on-year to ₹1,770 crore, as stated in the provided report. Total revenue for the quarter was reported at ₹1,783 crore, with net profit around ₹157 crore, alongside another reference to ₹156 crore profit before non-controlling interests. The same report noted EBITDA rising 9% to ₹286 crore, with an EBITDA margin of 16% of total sales. Another market note referenced EBITDA of ₹266 crore with a 16% margin for the quarter, reflecting that different summaries reported slightly different EBITDA figures. Profit before tax (PBT) for Q4 FY25 was reported at ₹191.95 crore, up 4.98% year-on-year. The core point across the Q4 coverage remained that sales improved while profit declined year-on-year. The provided explanation pointed to write-offs on impaired assets in previous years affecting taxation comparisons, as clarified by group CFO R K Baheti.

Segment picture in Q4: India, US, Ex-US and APIs

The segmental split for Q4 FY25 in the dataset showed API revenue of ₹342 crore, up 4% year-on-year. In formulations, India revenue was ₹545 crore, up 8% year-on-year. US revenue was ₹508 crore, up 20% year-on-year. Ex-US revenue was ₹375 crore, up 43% year-on-year. Management commentary in the report attributed the India-branded business performance to specialty therapies. The same report said the company made four launches in Q4 FY25 and 14 launches for the year in the India business. The animal health business grew 19% for the quarter, as stated. While API grew in the quarter, the report also said the API business declined 9% for the full year to ₹1,133 crore, with a stated reason of losing some large customers due to pricing competition. Taken together, the data suggests the quarter benefited from strong formulations growth, especially outside India, while APIs faced mixed conditions.

FY25 full-year numbers: revenue up, profit down

On a full-year basis, FY25 revenue from operations was reported at ₹6,672.08 crore, up 7.12% year-on-year. Consolidated net profit for FY25 fell 5.49% to ₹582.01 crore despite the revenue rise, according to the dataset. This combination of growth with lower net profit points to margin pressure, charges, mix, or cost movements, though the dataset does not provide a full reconciliation. The annual financial snapshot in the provided tables for Mar 25 also listed revenue of ₹6,032.63 crore and net income of ₹503.12 crore, which differs from the FY25 revenue and profit figures cited in the later report. These variations appear to reflect different data sources or consolidation scopes within the supplied text. Investors typically reconcile such differences by checking audited statements and defining whether numbers are standalone, consolidated, or for different periods. What is clearly stated is that the company reported higher sales in FY25 compared with the prior year, while net profit declined.

Reuters update: labour-code charge weighed on quarterly profit

A Reuters report in the supplied text said Alembic reported lower third-quarter profit after a one-time charge linked to India’s new labour code. Consolidated profit fell to 1.33 billion rupees, which is about ₹133 crore, for the quarter ended December 31, from 1.38 billion rupees, about ₹138 crore, a year earlier. The one-time charge was reported at 301 million rupees, about ₹30.1 crore. Reuters added that excluding this charge, profit rose nearly 15%. Revenue from operations jumped 11% to 18.76 billion rupees, which is about ₹1,876 crore. The same report highlighted strong demand for generic drugs and new product launches in the key US market. It also noted the broader sector got support after the US shelved plans to impose tariffs on generic drug imports. These details provide context for why reported profit could fall even as operating conditions improved.

Quarterly financial snapshot from the provided tables

The dataset included quarterly financials (in ₹ crore) showing fluctuating profitability. For Dec 25, revenue was ₹1,642.24 crore with net income of ₹114.47 crore and a net profit margin of 6.97%. For Sep 25, revenue was ₹1,796.24 crore with net income of ₹179.36 crore and margin of 9.98%. For Jun 25, revenue was ₹1,494.17 crore and net income ₹103.52 crore, margin 6.92%. For Mar 25 (quarter), revenue was ₹1,570.64 crore and net income ₹75.34 crore, margin 4.79%. Dec 24 showed revenue ₹1,406.09 crore and net income ₹85.81 crore, margin 6.1%. These figures indicate that margins moved meaningfully from quarter to quarter, which can influence market reactions around results. The dataset also provided EPS and tax rate figures, but it did not include a detailed bridge for margin changes.

Dividends and corporate action history in the dataset

The corporate action table listed multiple dividends over the years. The most recent entries included a final dividend of ₹11 with a dividend date of 29 Jul 2025 and record date of 29 Jul 2025, and another final dividend of ₹11 dated 15 Jul 2024. Earlier entries included ₹8 final in Jul 2023 and ₹10 interim in Aug 2022. The list extended back to 2012, showing regular payouts of varying amounts. This history indicates that dividends have been a recurring feature, though the dataset does not specify a formal policy statement. It also does not provide yield calculations, which would require the share price on relevant dates. For investors, dividend consistency is usually assessed alongside earnings stability and cash generation. The provided data includes a comment that the company has maintained a dividend payout of 39.4%, but no period definition is given in the snippet.

Key numbers at a glance

All figures are presented in ₹ crore unless stated otherwise.

Why these updates matter for investors

The provided numbers show a pattern where topline growth does not automatically translate into higher net profit. In Q4 FY25, sales rose strongly while profit declined year-on-year, implying higher costs, mix changes, charges, or other items that the dataset references only partially. Reuters adds another layer by flagging a labour-code-related one-time charge that reduced reported profit in a separate quarter, even as underlying profit rose on an adjusted basis. The segment data also highlights that growth was not uniform, with Ex-US and US formulations showing strong increases, while the API business faced competitive pressure and a full-year decline. For a company with a meaningful US exposure, approvals and launches can shift quarterly performance, as reflected in the Reuters mention of new product launches such as a hypertension treatment and an antidepressant. Market participants typically watch whether such launches sustain growth, but the dataset does not provide forward guidance. What is clear is that investors tracking the stock near ₹791.3 are weighing sales growth against profit volatility.

Conclusion

Alembic Pharma’s latest trading snapshot showed the stock near ₹791.3 with a wide 52-week band and negative one-year return in the provided data. Recent results highlighted strong Q4 FY25 revenue growth to ₹1,770 crore, but a year-on-year profit decline to around ₹157 crore, alongside an EBITDA margin around 16%. Separate reporting also pointed to a labour-code-linked one-time charge that lowered reported quarterly profit, even as revenue rose and adjusted profit improved. The next steps for investors, based on the dataset, are to track upcoming earnings timelines mentioned in the snippets and watch whether the growth in US and Ex-US formulations continues without further one-off impacts.